Sumitomo Mitsui DS Asset Management Company Ltd Grows Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Sumitomo Mitsui DS Asset Management increased its position in Alnylam Pharmaceuticals by 14.3%, owning a total of 14,808 shares worth approximately $4.83 million.
• Alnylam Pharmaceuticals reported a $0.32 EPS for the last quarter, beating estimates of ($0.54) by $0.86, with revenue increasing by 17.3% year-over-year.
• Multiple brokerages have recently raised their price targets for Alnylam Pharmaceuticals, with prices ranging from $475 to $570, indicating a strong analyst sentiment towards the company's stock.

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,808 shares of the biopharmaceutical company's stock after purchasing an additional 1,851 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Alnylam Pharmaceuticals were worth $4,829,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in ALNY. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $243,000. Cetera Investment Advisers increased its holdings in Alnylam Pharmaceuticals by 66.3% in the 4th quarter. Cetera Investment Advisers now owns 4,770 shares of the biopharmaceutical company's stock worth $1,122,000 after acquiring an additional 1,902 shares during the last quarter. Quantinno Capital Management LP increased its holdings in Alnylam Pharmaceuticals by 35.4% in the 4th quarter. Quantinno Capital Management LP now owns 4,556 shares of the biopharmaceutical company's stock worth $1,072,000 after acquiring an additional 1,190 shares during the last quarter. Vident Advisory LLC increased its holdings in Alnylam Pharmaceuticals by 21.2% in the 4th quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company's stock worth $312,000 after acquiring an additional 232 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $203,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 1.1%

Alnylam Pharmaceuticals stock traded down $5.26 during mid-day trading on Tuesday, hitting $453.66. The company had a trading volume of 72,280 shares, compared to its average volume of 975,507. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock's 50 day moving average price is $417.91 and its two-hundred day moving average price is $326.74. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The company has a market capitalization of $59.47 billion, a PE ratio of -183.06 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the company posted ($0.13) earnings per share. The company's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

ALNY has been the subject of several analyst reports. Barclays raised their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Royal Bank Of Canada boosted their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an "outperform" rating in a research report on Friday. BMO Capital Markets boosted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Finally, JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $439.58.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,274 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the sale, the executive vice president owned 50,121 shares in the company, valued at approximately $22,718,345.67. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Colleen F. Reitan sold 18,000 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the sale, the director owned 775 shares of the company's stock, valued at approximately $362,390. This trade represents a 95.87% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 75,594 shares of company stock valued at $33,968,256. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.